Published in

Elsevier, The Lancet Diabetes and Endocrinology, 10(4), p. 840-849, 2016

DOI: 10.1016/s2213-8587(16)30196-6

Links

Tools

Export citation

Search in Google Scholar

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

Journal article published in 2016 by Peter Willeit, Stephen Kaptoge, Paul Welsh, Adam S. Butterworth, Rajiv Chowdhury ORCID, Paul Welsh Stephen Kaptoge, Sarah A. Spackman, Lisa Pennells, A. Spackman Sarah, Pei Gao, Stephen Burgess ORCID, Daniel F. Freitag, Michael Sweeting, Angela M. Wood, R. Cook Nancy and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment. METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie,